GB2283171A - Pharmaceutical product for treatment of reflux oesophagitis,gastritis or peptic ulceration - Google Patents
Pharmaceutical product for treatment of reflux oesophagitis,gastritis or peptic ulceration Download PDFInfo
- Publication number
- GB2283171A GB2283171A GB9411350A GB9411350A GB2283171A GB 2283171 A GB2283171 A GB 2283171A GB 9411350 A GB9411350 A GB 9411350A GB 9411350 A GB9411350 A GB 9411350A GB 2283171 A GB2283171 A GB 2283171A
- Authority
- GB
- United Kingdom
- Prior art keywords
- carbonate
- pharmaceutical product
- product according
- oil
- polymeric material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 35
- 229920000615 alginic acid Polymers 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 23
- 239000002775 capsule Substances 0.000 claims abstract description 21
- 239000000783 alginic acid Substances 0.000 claims abstract description 17
- 229960001126 alginic acid Drugs 0.000 claims abstract description 17
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 17
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 17
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000001828 Gelatine Substances 0.000 claims abstract description 10
- 229920000159 gelatin Polymers 0.000 claims abstract description 10
- 235000019322 gelatine Nutrition 0.000 claims abstract description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims abstract description 8
- 210000002784 stomach Anatomy 0.000 claims abstract description 8
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract description 6
- 206010057969 Reflux gastritis Diseases 0.000 claims abstract description 6
- 229920001525 carrageenan Polymers 0.000 claims abstract description 6
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 6
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920002148 Gellan gum Polymers 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- 235000010987 pectin Nutrition 0.000 claims abstract description 5
- 229920001277 pectin Polymers 0.000 claims abstract description 5
- 239000001814 pectin Substances 0.000 claims abstract description 5
- 230000037406 food intake Effects 0.000 claims abstract description 3
- 230000035515 penetration Effects 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 11
- 229940072056 alginate Drugs 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 6
- 239000001095 magnesium carbonate Substances 0.000 claims description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 159000000007 calcium salts Chemical class 0.000 claims description 5
- 235000019864 coconut oil Nutrition 0.000 claims description 5
- 239000003240 coconut oil Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 claims description 4
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 4
- 239000011736 potassium bicarbonate Substances 0.000 claims description 4
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 229960004018 magaldrate Drugs 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 150000001399 aluminium compounds Chemical class 0.000 claims description 2
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 claims description 2
- LHPJBAIYHPWIOT-UHFFFAOYSA-K aluminum;magnesium;carbonate;hydroxide Chemical compound [OH-].[Mg+2].[Al+3].[O-]C([O-])=O LHPJBAIYHPWIOT-UHFFFAOYSA-K 0.000 claims description 2
- PCRDIRUKXOTDNN-UHFFFAOYSA-K aluminum;sodium;carbonate;hydroxide Chemical compound [OH-].[Na+].[Al+3].[O-]C([O-])=O PCRDIRUKXOTDNN-UHFFFAOYSA-K 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 2
- JYIMWRSJCRRYNK-UHFFFAOYSA-N dialuminum;disodium;oxygen(2-);silicon(4+);hydrate Chemical compound O.[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Al+3].[Al+3].[Si+4] JYIMWRSJCRRYNK-UHFFFAOYSA-N 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 229940042472 mineral oil Drugs 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- LCWAOCHOPBSGMU-UHFFFAOYSA-J aluminum;magnesium;sodium;hydrogen carbonate;oxygen(2-);silicon;trihydroxide Chemical compound [OH-].[OH-].[OH-].[O-2].[Na+].[Mg+2].[Al+3].[Si].OC([O-])=O LCWAOCHOPBSGMU-UHFFFAOYSA-J 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 229940045140 gaviscon Drugs 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- -1 aluminium ions Chemical class 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229940016060 calcium carbonate 150 mg Drugs 0.000 description 1
- 229940016038 calcium carbonate 30 mg Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940031625 pectin 300 mg Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001407 sodium bicarbonate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical product for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of a chewable soft gelatine capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle; wherein on oral ingestion by a patient the gelatine capsule shell ruptures and the fill reacts with the acid contents of the stomach to produce a carbonated floating gelatinous raft of specified rigidity.
Description
PHARMACEUTICAL PRODUCTS
This invention relates to pharmaceutical products and in particular to compositions for the treatment of reflux oesophagitis, gastritis or peptic ulceration.
Reflux oesophagitis occurs when small amounts of gastric juice, food and/or bile acids pass into the lower part of the oesophagus and cause oesophageal inflammation accompanied by pain which may manifest itself in the form of heartburn.
One approach to the problem of reflux oesophagitis comprises the administration of a preparation which on contact with gastric acid generates a carbonated gelatinous foam or raft which floats on the stomach contents. When reflux occurs it is this raft which precedes the stomach contents into the oesophagus thus protecting the mucosa from further irritation. Known preparations of this type included solid preparation in the form of powders or tablets containing alginic acid, sodium bicarbonate and antacid materials or liquid preparations containing sodium alginate, sodium bicarbonate and calcium carbonate marketed under the name GAVISCON (TM Reckitt & Colman Products Ltd). In our
British Patent No. 1524740 we describe such liquid preparations. In our corresponding German Patent No 2738014 C2 we describe a penetration test used for evaluating raft rigidity.The procedure described is based on ASTM D217-68 "Standard Method for Cone Penetration of
Lubricating Grease". In the method described in the patent a lightweight cone assembly of a penetrometer is released and allowed to penetrate into the raft, the depth of penetration being measured.
In our US Patent No. 4172120 we describe a preparation including cholestyramine which is retained in the stomach for a prolonged period of time and is therefore more effective in binding duodenally ref fluxed bile. This preparation includes alginic acid and/or sodium alginate together with sodium bicarbonate which on being swallowed react with gastric acid to form a carbonated raft which holds the cholestryamine sufficiently loosely that it is able to absorb bile acid in the stomach.
The carbonated alginic acid raft type of product is further exemplified by ALGICON (Rhone-Poulenc Rorer) described in European Patent No. 0179858 B1 as containing magnesium alginate, potassium bicarbonate, magnesium carbonate and as antacid materials aluminium hydroxide/magnesium carbonate co-dried gel.
According to the present invention there is provided a pharmaceutical product for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of a chewable soft gelatine capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle; wherein on oral ingestion the gelatine capsule shell ruptures and the fill reacts with the acid contents of the stomach thereby producing a carbonated floating gelatinous raft of such rigidity that in the penetration test there is not complete penetration.
By complete penetration we mean that the cone of the penetrometer passes completely through the raft.
Preferably the polymeric material is the sodium, potassium, ammonium, magnesium or calcium salt of alginic acid or the propylene glycol esters or mixtures thereof.
We have shown that when the polymeric material is alginic acid or a salt or ester thereof rafts of improved strength are obtained if the composition includes a source of diva lent calcium or trivalent aluminium ion which act as cross-linking agents. Suitable sources of calcium ions are those derived from the carbonate, lactate, chloride, gluconate, phosphate, hydrogen phosphate, sulphate, tartrate or citrate salts. Suitable sources of aluminium ions are those derived from the carbonate, lactate, glycinate or phosphate salts or from aluminium magnesium carbonate hydroxide, magaldrate, aluminium sodium carbonate hydroxide or aluminium sodium silicate. Conveniently the relative quantities by weight of the calcium salt or aluminium compound to the alginic acid or alginate calculated as ions are 4 to 120 Ca2+ to 500 alginate' or 2 to 80 A13+ to 500 alginate' respectively.
Suitable carbonate or bicarbonate salts are potassium carbonate or bicarbonate, sodium carbonate or bicarbonate, calcium carbonate, sodium glycine carbonate, magnesium carbonate or aluminium carbonate. The carbonate or bicarbonate salt is present in an amount so as to provide an adequate volume of gas (carbon dioxide) to float the gel produced when the polymeric material contacts the gastric acid in the stomach. Preferably the relative quantities by weight of polymeric material to the carbonate or bicarbonate calculated as ions is 35 to 300 CO32 or HC03- to 500 polymeric material.
It will be understood that the rigidity and thickness of the carbonated raft formed on contact with the gastric acid will depend upon the ratio of carbonate or bicarbonate to the polymeric material and upon the grade of the polymeric material.
Suitable oil-based liquid vehicles are natural oils such as soya bean oil, fractionated coconut oil, mineral oils, triacetin, ethyl oleate, hydrogenated natural oil and mixtures thereof.
Suitable hydrophilic based liquid vehicles are polyethylene glycols (PEG's) particularly PEG 400 and PEG 600, glycofurol, polyglycerols, propylene glycol,
Transcutol, polysorbate and propylene carbonate and mixtures thereof.
The invention also includes a method of treating reflux oesophagitis, gastritis or peptic ulceration which comprises administration of an effective amount of a product which is capable of forming a floating gelatinous raft when contacted with the acid contents of the stomach said raft being of such rigidity that in the penetration test there is not complete penetration and said product being in the form of a chewable soft gelatine capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle.
The gelatine capsules may be simultaneously formed and filled using conventional methods and apparatus such as disclosed, for example, in an article by H. Seager in
Pharmaceutical Technology September 1985. Thus all the ingredients of the fill material including the liquid vehicle are mixed together, with heating if necessary, until the desired consistency for filling and the desired uniformity is obtained. The encapsulation machine is suitably an R P Scherer encapsulation machine.
In order to facilitate the even dispersion of the solid components of the fill in the liquid vehicle a surfactant may be included in the fill.
In the fill the polymeric materials will have a thickening effect upon the liquid fill. This thickening effect may be further increased if so desired by the inclusion of a thickening agent such as hydrogenated vegetable oils, glyceryl monostearate, glyceryl monopalmitate, beeswax (or other high melting point fat or wax) or a dispersed thickener such as colloidal silicon dioxide. For hydrophilic vehicles, a suitable thickening agent may be one or more high molecular weight PEG's."
The capsules will be suitably shaped and sized so as to be readily ingestible by a person following chewing.
The invention is illustrated by the following Examples:
ExamPle 1
Capsules in a standard gelatine shell were prepared having the following fill:
Quantity/Capsule
Sodium Alginate (Protanal LF5/60) 500 mg
Sodium Bicarbonate BP 100 mg
Calcium Carbonate 30 mg
Fractionated Coconut Oil BP 600 mg
Lecithin 12 mg
Colloidal Silicon Dioxide 34 mg
Sorbitan Fatty Acid Esters 34 mg
Polysorbate 80 BP 20 mg
Flavouring, colouring, sweetener 80 mg
1410 mg
Example 2
Capsules were prepared as in Example 1 except that the amount of calcium carbonate in the fill materials was increased to 100 mg.
Example 3
Capsules were prepared as in Example 1 having the following fill:
Quantity/Capsule
Sodium Alginate 500 mg
Xanthan Gum 100 mg
Sodium Bicarbonate 100 mg
Calcium Carbonate 100 mg
Aerosil 35 mg
Flavour, Sweetener qs
Soya Bean Oil qs ad
1500 mg
Example 4
Capsules were prepared as in Example 1 having the following fill:
Quantity/Capsule
Alginic Acid 500 mg
Carrageenan 100 mg
Sodium Carbonate 100 mg
Calcium Chloride 100 mg Aeros il 35 mg
Polysorbate 80 20 mg
Flavour, Sweetener qs
Fractionated Coconut Oil qs ad
1500 mg
Example 5
Capsules were prepared as in Example 1 having the following fill::
Quantity/Capsule
Magnesium Alginate 500 mg
Gellan Gum 50 mg
Magaldrate 200 mg
Sodium Bicarbonate 150 mg
Glyceryl Mono-Stearate 100 mg
Polysorbate 80 20 mg
Flavour, Sweetener qs
Fractionated Coconut Oil qs ad
1600 mg Example 6
Capsules were prepared as in Example 1 having the following fill:
Quantity/Capsule
Alginic Acid 300 mg
Pectin 300 mg
Calcium Carbonate 150 mg
Sodium Bicarbonate 150 mg
Hydrogenated Vegetable Oil 150 mg
Lecithin 15 mg
Flavour, Sweetener qs
Arachis Oil qs ad
1550 mg
The rigidity of the rafts produced by the products of
Examples 1 and 2 were assessed by a cone penetration test adapted from ASTM D217-68. This method had been previously described for the determination of alginate raft rigidity in our German Patent No DE 273801 C2.In this patent we used a metal cone assembly of weight 26.0g (cf a weight of 150.0g of ASTM D217-68) as shown in Fig 1.
Tests were also carried out on two comparative Examples (a) Liquid Gaviscon (Reckitt & Colman Products Ltd) containing sodium alginate 500 mg, sodium bicarbonate 267 mg, calcium carbonate 160 mg per 10 ml and (b) Algicon suspension (Rhone-Poulenc Rorer) containing magnesium alginate 250 mg, aluminium hydroxide/magnesium carbonate codried gel 140 mg, magnesium carbonate 175 mg, potassium bicarbonate 50 mg per 5 ml.
Preparation of raft samples
The raft was prepared as follows: a bulk sample was prepared sufficient for 6 rafts.
In the case of Examples 1 & 2, the appropriate amount of product (equivalent to 6 doses of 1g of polymeric material) was weighed and added to a 250ml tall-form beaker (height 120mm & diameter 60mm) previously weighed. A volume of 120ml of deionised water was added and the mixture homogenized for 5 minutes using the Silverson Model L4R homogenizer with a Turbular Unit 1" in diameter and a square hole high shear screen. The speed of the homogenizer was set at speed 4 / 5000-5200 rpm. In the case of Liquid
Gaviscon and Algicon Mint, 120ml of the product was taken and added to a 250ml tall-form beaker. A volume of 120ml of deionized water was added and the mixture homogenized for 5 minutes as before.
After homogenization, a quantity of homogenized mixture equivalent to 1g of polymeric material was added to 150mls 0.1M HCl in a 250ml low-form beaker (height 94mm & diameter 67mm) preheated to 370C, using a 50ml Plastipak syringe with 60ml scale and lok tip. The raft was allowed to stand for 30 minutes. After that time, the raft depth was measured and the cone penetration test carried out.
Description of the method
The Cone Penetration test was carried out using a
Penetrometer (Stanhope-Seta, Surrey England) fitted with the cone arrangement described above of weight 26.0g. The tip of the cone was brought carefully into contact with the upper surface of the raft, the dial micrometer arm was brought into contact with the upper surface of the cone assembly, and the dial micrometer was zeroed. The spring loaded release button was depressed for approximately one second, and the cone assembly was allowed to sink into the raft. The centre knob on the dial micrometer was turned to bring the micrometer arm again into full contact with the upper surface of the cone assembly. The depth of penetration was recorded, this being inversely proportional to the rigidity of the raft. The mean of 5 raft evaluations was calculated. The results obtained are set out in the
Table.
TABLE
Product Raft Depth Penetration Depth Penetration (mm) (mm) (%) 34 22.1 65.00 Example 1 33 24.0 75.45 34 29.2 85.88 31 12.1 39.03 Mean = 33 Mean = 22.08 Mean = 66.34 34 10.5 30.88 34 7.7 22.65 Example 2 30 9.3 31.00 33 9.8 29.70 33 10.6 32.12 Mean = 32.8 Mean = 9.58 Mean = 29.27 37 9.7 26.22 40 9.5 23.75 Liquid 42 12.8 30.48 Gaviscon 40 8.7 21.75 40.5 11.1 27.41 Mean = 39.9 Mean = 10.36 Mean = 25.92 34 Complete 100 36 " 100 Algicon 32 " 100 34 .. 100 36.5 " " 100 Mean = 16.0 Mean = Complete Mean = 100 In the case of Algicon the cone of the penetrometer passed completely through the rafts.
Claims (15)
1. A pharmaceutical product for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of a chewable soft gelatine capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle; wherein on oral ingestion th gelatine capsule shell ruptures and the fill reacts with the acid contents of the stomach thereby producing a carbonated floating gelatinous raft of such rigidity that in the penetration test there is not complete penetration.
2. A pharmaceutical product according to Claim 1 wherein the polymeric material is alginic acid or the alginates, are the sodium, potassium, ammonium, magnesium or calcium salts or the propylene glycol esters or mixtures thereof.
3. A pharmaceutical product according to Claim 2 which includes a calcium or aluminium cross-linking ion.
4. A pharmaceutical product according to Claim 3 wherein the calcium ion is derived from the carbonate, lactate, chloride, gluconate, phosphate, hydrogen phosphate, sulphate, tartrate or citrate salt.
5. A pharmaceutical product according to Claim 3 wherein the aluminium ion is derived from the carbonate, lactate, glycinate or phosphate salt or from, aluminium magnesium carbonate hydroxide, magaldrate, aluminium sodium carbonate hydroxide or aluminium sodium silicate.
6. A pharmaceutical product according to Claim 4 wherein the relative quantities by weight of the calcium salt to the alginic acid or alginate calculated as ions is 4 to 120 Ca2+ to 500 alginate'.
7. A pharmaceutical product according to Claim 5 wherein the relative quantities by weight of the aluminium compound to the alginic acid or alginate calculated as ions is 2 to 80 Al3+ to 500 alginate'.
8. A pharmaceutical product according to any of the preceding Claims wherein the carbonate or bicarbonate salt is potassium carbonate or bicarbonate, sodium carbonate or bicarbonate, calcium carbonate, sodium glycine carbonate, magnesium carbonate or aluminium carbonate.
9. A pharmaceutical product according to any of the preceding Claims wherein the relative quantities by weight of carbonate or bicarbonate to the polymeric material calculated as ions is 35 to 300 CO32 or HCO3- to 500 polymeric material.
10. A pharmaceutical product according to any of the preceding Claims wherein the oil-based liquid vehicle is a natural oil such as soya bean oil, fractionated coconut oil, mineral oil, triacetin, ethyl oleate, a hydrogenated natural oil or mixture thereof.
11. A pharmaceutical product according to any one of Claims 1 to 9 wherein the hydrophilic based liquid vehicle is a polyethylene glycol (PEG's) particularly PEG 400 and PEG 600, glycofurol, polyglycerols, propylene glycol, transcutol, polysorbate, propylene carbonate or mixtures thereof.
12. A pharmaceutical product according to any of the preceding Claims wherein the fill includes a thickening agent.
13. A pharmaceutical product according to any of the preceding Claims wherein the fill includes a surfactant.
14. A method of treating reflux oesophagitis, gastritis or peptic ulceration which comprises administration of an effective amount of a product which is capable of forming a floating gelatinous raft when contacted with the acid contents of the stomach said raft being of such rigidity that in the penetration test there is not complete penetration and said product being in the form of a chewable soft gelatine capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle.
15. A method according to Claim 14 wherein the polymeric material is alginic acid or the alginates, are the sodium, potassium, ammonium, magnesium or calcium salts or the propylene glycol esters or mixtures thereof.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ27490194A NZ274901A (en) | 1993-10-29 | 1994-10-28 | Chewable gelatin capsule for the treatment of gastric reflux or peptic ulceration comprising polymeric material, carbonate or bicarbonate salt and oil or hydrophilic based liquid vehicle |
| AU80004/94A AU8000494A (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
| CA 2174777 CA2174777A1 (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
| CN 94193934 CN1133558A (en) | 1993-10-29 | 1994-10-28 | Expandable Gelatin Capsules to Fill Drugs |
| BR9407916A BR9407916A (en) | 1993-10-29 | 1994-10-28 | Pharmaceutical product and process for treatment of reflux esophagitis gastritis or peptic ulcer |
| PCT/GB1994/002380 WO1995011668A1 (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
| JP7512497A JPH09504286A (en) | 1993-10-29 | 1994-10-28 | Effervescent gelatin capsule filling |
| EP94931124A EP0725626A1 (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
| KR1019960702194A KR960705552A (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
| NO961638A NO961638D0 (en) | 1993-10-29 | 1996-04-24 | Gel foam capsule fillers that can foam |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939322314A GB9322314D0 (en) | 1993-10-29 | 1993-10-29 | Foam generating capsules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9411350D0 GB9411350D0 (en) | 1994-07-27 |
| GB2283171A true GB2283171A (en) | 1995-05-03 |
| GB2283171B GB2283171B (en) | 1997-12-10 |
Family
ID=10744318
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB939322314A Pending GB9322314D0 (en) | 1993-10-29 | 1993-10-29 | Foam generating capsules |
| GB9411388A Withdrawn GB2283172A (en) | 1993-10-29 | 1994-06-07 | Gelatin capsules |
| GB9411350A Expired - Fee Related GB2283171B (en) | 1993-10-29 | 1994-06-07 | Pharmaceutical products |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB939322314A Pending GB9322314D0 (en) | 1993-10-29 | 1993-10-29 | Foam generating capsules |
| GB9411388A Withdrawn GB2283172A (en) | 1993-10-29 | 1994-06-07 | Gelatin capsules |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR960705552A (en) |
| GB (3) | GB9322314D0 (en) |
| ZA (2) | ZA948512B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029054A1 (en) * | 1995-03-17 | 1996-09-26 | The Boots Company Plc | Pectin pharmaceutical compositions |
| GB2324725A (en) * | 1997-04-30 | 1998-11-04 | Reckitt & Colmann Prod Ltd | Alinate/Alginic Acid Composition |
| GB2349570A (en) * | 1999-05-05 | 2000-11-08 | Reckitt & Colmann Prod Ltd | Compositions for treatment of disorders of the oesophagus |
| US6635279B2 (en) | 2000-03-27 | 2003-10-21 | Basf Aktiengesellschaft | Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production |
| AU2001258538B2 (en) * | 2000-05-19 | 2005-04-21 | Reckitt Benckiser Healthcare(Uk) Limited | Pepsin inhibition by alginates |
| US8293270B2 (en) * | 2005-10-26 | 2012-10-23 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system |
| EP4366792A4 (en) * | 2021-07-05 | 2025-05-28 | Reflux Gourmet LLC | ALGINATE, POLYLYSIN AND SEED-BASED PRESERVATIVE NUTRITIONAL PRODUCT AND DIGESTION AID |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0814773B1 (en) * | 1995-03-17 | 2001-07-25 | The Boots Company PLC | Pectin liquid pharmaceutical compositions |
| AU5060499A (en) * | 1999-08-04 | 2001-03-05 | Ranbaxy Laboratories Limited | Hydrodynamically balanced oral drug delivery system |
| EP1959935A2 (en) | 2005-10-26 | 2008-08-27 | Banner Pharmacaps Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
| WO2019169137A1 (en) * | 2018-03-02 | 2019-09-06 | Pharagen Llc | Formulations treating acid reflux comprising sodium alginate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172120A (en) * | 1977-03-10 | 1979-10-23 | Reckitt & Colman Products Limited | Cholestyramine compositions and method for treating biliary gastritis |
| GB2222772A (en) * | 1988-09-20 | 1990-03-21 | Glaxo Group Ltd | Pharmaceutical compositions containing ranitidine |
-
1993
- 1993-10-29 GB GB939322314A patent/GB9322314D0/en active Pending
-
1994
- 1994-06-07 GB GB9411388A patent/GB2283172A/en not_active Withdrawn
- 1994-06-07 GB GB9411350A patent/GB2283171B/en not_active Expired - Fee Related
- 1994-10-28 ZA ZA948512A patent/ZA948512B/en unknown
- 1994-10-28 ZA ZA948506A patent/ZA948506B/en unknown
- 1994-10-28 KR KR1019960702194A patent/KR960705552A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172120A (en) * | 1977-03-10 | 1979-10-23 | Reckitt & Colman Products Limited | Cholestyramine compositions and method for treating biliary gastritis |
| GB2222772A (en) * | 1988-09-20 | 1990-03-21 | Glaxo Group Ltd | Pharmaceutical compositions containing ranitidine |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029054A1 (en) * | 1995-03-17 | 1996-09-26 | The Boots Company Plc | Pectin pharmaceutical compositions |
| GB2324725A (en) * | 1997-04-30 | 1998-11-04 | Reckitt & Colmann Prod Ltd | Alinate/Alginic Acid Composition |
| GB2324725B (en) * | 1997-04-30 | 2001-10-17 | Reckitt & Colmann Prod Ltd | Organic compositions |
| GB2349570A (en) * | 1999-05-05 | 2000-11-08 | Reckitt & Colmann Prod Ltd | Compositions for treatment of disorders of the oesophagus |
| GB2349570B (en) * | 1999-05-05 | 2002-05-22 | Reckitt & Colmann Prod Ltd | Compositions for treatment of disorders of the oesophagus associated with reflux |
| US6610667B1 (en) | 1999-05-05 | 2003-08-26 | Reckitt Benckiser Healthcare (Uk) Limited | Compositions for treatment of disorders of the oesophagus |
| US6635279B2 (en) | 2000-03-27 | 2003-10-21 | Basf Aktiengesellschaft | Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production |
| AU2001258538B2 (en) * | 2000-05-19 | 2005-04-21 | Reckitt Benckiser Healthcare(Uk) Limited | Pepsin inhibition by alginates |
| US8293270B2 (en) * | 2005-10-26 | 2012-10-23 | Banner Pharmacaps, Inc. | Lipophilic vehicle-based dual controlled release matrix system |
| EP4366792A4 (en) * | 2021-07-05 | 2025-05-28 | Reflux Gourmet LLC | ALGINATE, POLYLYSIN AND SEED-BASED PRESERVATIVE NUTRITIONAL PRODUCT AND DIGESTION AID |
| EP4366742A4 (en) * | 2021-07-05 | 2025-09-17 | Reflux Gourmet Llc | METHOD FOR NEUTRALIZING GASTRIC ACID USING ALGINATE, POLYLYSINE AND SEED PRESERVATIVES |
Also Published As
| Publication number | Publication date |
|---|---|
| KR960705552A (en) | 1996-11-08 |
| ZA948506B (en) | 1995-06-22 |
| GB2283171B (en) | 1997-12-10 |
| GB9411388D0 (en) | 1994-07-27 |
| GB9411350D0 (en) | 1994-07-27 |
| GB9322314D0 (en) | 1993-12-15 |
| ZA948512B (en) | 1995-09-20 |
| GB2283172A (en) | 1995-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1267090A (en) | Aerosol foam | |
| CA1272134A (en) | Drug delivery system | |
| CA1149282A (en) | Chewing gum capable of releasing finely divided water-insoluble materials therefrom | |
| CA1319106C (en) | Antacid composition | |
| GB2283171A (en) | Pharmaceutical product for treatment of reflux oesophagitis,gastritis or peptic ulceration | |
| CA2174777A1 (en) | Gelatin capsule fill able to foam | |
| JPS6219054A (en) | Laminar chewing gum having moisture impermeable outer layer | |
| US9452135B2 (en) | Gelling agent-based dosage form | |
| US5888540A (en) | Pharmaceutical products | |
| DE69423812T2 (en) | New floating antacid compositions | |
| EP0179858A4 (en) | Antacid composition. | |
| AU692483B2 (en) | Gelatin capsule fill able to foam | |
| US5173305A (en) | Composition for protection of oesogastroduodenal mucous membrane | |
| JPH0150205B2 (en) | ||
| AU614962C (en) | An antacid composition | |
| IL105870A (en) | Pharmaceutical soft capsules containing lysine clonixinate and their preparation | |
| JP2005047809A (en) | Gel composition for internal use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19980607 |